ZMYND8 and Miyoshi myopathy: Importantly, we showed that ZMYND8 acts as a direct inhibitor of NSD2‐induced H3K36me2 signaling in MM, providing a unique molecular perspective for the inhibition of oncogenic H3K36me2 pathways.